Isobutyryl-carbamic acid benzyl ester | 69261-51-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Isobutyryl-carbamic acid benzyl ester
• 英文别名: benzyl N-(2-methylpropanoyl)carbamate
• CAS: 69261-51-4
• 化学式: C₁₂H₁₅NO₃
• 分子量: 221.256
• InChiKey: JWVSYRHSJHPVEH-UHFFFAOYSA-N

物化性质

• 密度：
  1.117±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Isobutyryl-carbamic acid benzyl ester 在 3-(1-piperidino)propyl functionalized silica gel (SiO₂-Pip) 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 3-(N-benzyloxycarbonylamino)-4-methyl-1-phenylpentan-1-one
  参考文献：
  名称：

  1-（N-酰基氨基）烷基三苯基phosph盐与甲硅烷基烯醇盐的无催化剂曼尼希型反应

  摘要：

  开发了四氟硼酸1-（N-酰基氨基）烷基三苯基phosph与烯丙基甲硅烷基酯的无催化剂反应，以制备β-氨基羰基化合物。所报道的方法是用于制备N-保护的β-氨基酯以及N-保护的β-氨基酮的有用方法。起始的1-（N-酰基氨基）烷基三苯基phosph四氟硼酸酯可容易地从N-保护的α-氨基酸获得。因此，提出的方法可以被认为是一种新的方法，用于N-保护的α-氨基酸的α-同源制备β-氨基酸衍生物。

  DOI：

  10.1016/j.tet.2018.12.042

文献信息

• Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus
  申请人：Seattle Genetics, Inc.

  公开号：US10000555B2

  公开（公告）日：2018-06-19

  Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The related conjugates can target specific cell types to provide therapeutic benefit.

  提供的 MeVal-Val-Dil-Dap-Phe (MMAF) Auristatin 肽类似物具有 C 端苯丙氨酸残基侧链替换或修饰，可单独提供或通过各种连接体连接到配体上。相关共轭物可靶向特定细胞类型，提供治疗效果。
• Urea derivative or pharmacologically acceptable salt thereof
  申请人：KYORIN PHARMACEUTICAL CO., LTD.

  公开号：US10858314B2

  公开（公告）日：2020-12-08

  The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea compound or the pharmacologically acceptable salt thereof and a pharmaceutical use thereof. It has been found that a urea derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like.

  本发明提供了一种具有类似甲酰肽受体1（以下可简称为FPRL1）激动剂效应的脲化合物或其药理学上可接受的盐、一种含有该脲化合物或其药理学上可接受的盐的药物组合物及其药物用途。研究发现，由以下通式（I）代表的脲衍生物或其药理学上可接受的盐具有优异的 FPRL1 激动剂效果。化合物(I)或其药理学上可接受的盐在治疗、预防或抑制炎症性疾病、慢性气道疾病、癌症、败血症、过敏症状、HIV逆转录病毒感染、循环系统疾病、神经炎症、神经紊乱、疼痛、朊病毒病、淀粉样变性、免疫紊乱等方面非常有用。
• Bivalent bromodomain inhibitors and uses thereof
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10913752B2

  公开（公告）日：2021-02-09

  The present invention provides bivalent inhibitors of BET bromodomains, such as compounds of Formulae (I), (II), (III), (IV), (V), and (VI). Some bromdomain-containing proteins (e.g., BRD4) have a tandem bromodomain primary structure comprising more than one bromodomain binding site (e.g., BRD4 comprises BD1 and BD2). Bivalent inhibitors of BET bromodomains provided herein can target bromodomains through advantageous multivalent interactions, and can therefore can be to treat diseases or conditions associated with bromodomain-containing proteins. The present also provides pharmaceutical compositions and kits comprising the inventive compounds, as well as methods of using the inventive compounds.

  本发明提供了BET溴域的二价抑制剂，如式(I)、(II)、(III)、(IV)、(V)和(VI)的化合物。某些含溴结构域的蛋白质（如 BRD4）具有串联溴结构域一级结构，包含一个以上的溴结构域结合位点（如 BRD4 包含 BD1 和 BD2）。本发明提供的 BET 溴链的二价抑制剂可通过有利的多价相互作用靶向溴链，因此可用于治疗与含溴链蛋白相关的疾病或病症。本发明还提供了包含本发明化合物的药物组合物和试剂盒，以及使用本发明化合物的方法。
• UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF
  申请人：KYORIN PHARMACEUTICAL CO., LTD.

  公开号：US20180208552A1

  公开（公告）日：2018-07-26

  The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea compound or the pharmacologically acceptable salt thereof, and a pharmaceutical use thereof. It has been found that a urea derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like.
• BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20200172553A9

  公开（公告）日：2020-06-04

  The present invention provides bivalent inhibitors of BET bromodomains, such as compounds of Formulae (I), (II), (III), (IV), (V) and (VI). Some bromdomain-containing proteins (e.g., BRD4) have a tandem bromodomain primary structure comprising more than one bromodomain binding site (e.g., BRD4 comprises BD1 and BD2). Bivalent inhibitors of BET bromodomains provided herein can target bromodomains through advantageous multivalent interactions, and can therefore can be to treat diseases or conditions associated with bromodomain-containing proteins. The present also provides pharmaceutical compositions and kits comprising the inventive compounds, as well as methods of using the inventive compounds.